204 related articles for article (PubMed ID: 19958090)
1. Genetic determinants of warfarin dosing in the Han-Chinese population.
Lee MT; Chen CH; Chou CH; Lu LS; Chuang HP; Chen YT; Saleem AN; Wen MS; Chen JJ; Wu JY; Chen YT
Pharmacogenomics; 2009 Dec; 10(12):1905-13. PubMed ID: 19958090
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
[TBL] [Abstract][Full Text] [Related]
3. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
4. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
6. [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
Lou Y; Han L; Li Y; Zhang X; Liu Z; Tang M; Yu H; Wang W; Xu J; Liu H; Li Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):367-71. PubMed ID: 24928022
[TBL] [Abstract][Full Text] [Related]
7. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients.
Choi JR; Kim JO; Kang DR; Yoon SA; Shin JY; Zhang X; Roh MO; Hong HJ; Wang YP; Jo KH; Lee KS; Yun HJ; Oh YS; Yoo KD; Jeon HG; Lee YS; Kang TS; Park HJ; Chung MW; Kang JH
J Hum Genet; 2011 Apr; 56(4):290-5. PubMed ID: 21326313
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
9. Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients.
Xu Q; Zhang S; Wu C; Xiong Y; Niu J; Li F; Zhu J; Shen L; Zhu B; Xing Q; He L; Chen L; Li M; Li H; Ge J; Qin S
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e105-e111. PubMed ID: 33958549
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing warfarin dose requirements in African-Americans.
Momary KM; Shapiro NL; Viana MA; Nutescu EA; Helgason CM; Cavallari LH
Pharmacogenomics; 2007 Nov; 8(11):1535-44. PubMed ID: 18034618
[TBL] [Abstract][Full Text] [Related]
11. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
12. Association of genetic polymorphisms with warfarin dose requirements in Chinese patients.
Liang Y; Chen Z; Guo G; Dong X; Wu C; Li H; Wang T; Xu B
Genet Test Mol Biomarkers; 2013 Dec; 17(12):932-6. PubMed ID: 23941071
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
14. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Lu Y; Yang J; Zhang H; Yang J
Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
[TBL] [Abstract][Full Text] [Related]
15. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.
Zhang W; Zhang WJ; Zhu J; Kong FC; Li YY; Wang HY; Yang YH; Wang C
Pharmacogenomics; 2012 Feb; 13(3):309-21. PubMed ID: 22248286
[TBL] [Abstract][Full Text] [Related]
17. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
19. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
[TBL] [Abstract][Full Text] [Related]
20. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]